PMID- 28418286
OWN - NLM
STAT- MEDLINE
DCOM- 20170728
LR  - 20201209
IS  - 1532-2513 (Electronic)
IS  - 0892-3973 (Linking)
VI  - 39
IP  - 3
DP  - 2017 Jun
TI  - External application of NF-kappaB inhibitor DHMEQ suppresses development of atopic 
      dermatitis-like lesions induced with DNCB/OX in BALB/c mice.
PG  - 157-164
LID - 10.1080/08923973.2017.1312436 [doi]
AB  - CONTEXT: Dehydroxymethylepoxyquinomicin (DHMEQ) which is originally developed as 
      an analog of antibiotic epoxyquinomicin C is a specific and potent inhibitor of 
      NF-kappaB and has been shown to possess promising potential as an anti-inflammatory 
      and anti-tumor agent. OBJECTIVE: This study examines DHMEQ's effect on 
      therapeutic potential for atopic dermatitis (AD)-like lesions. MATERIALS AND 
      METHODS: AD lesions were chronically induced by the repetitive and alternative 
      application of 2,4-dinitrochlorobenzene (DNCB) and oxazolone (OX) on ears in 
      BALB/c mice. The mice were then externally treated with DHMEQ ointment. 
      Macroscopic and microscopic changes of the skin lesions were observed and 
      recorded. RESULTS: DHMEQ inhibited ear swelling and relieved clinical symptoms of 
      the AD-like lesions induced by DNCB/OX in BALB/c mice. Histopathology examination 
      illustrated that it significantly decreased DNCB/OX-induced epidermal thickness, 
      the infiltration of inflammatory cells, and the count of mast cell. The elevated 
      level of immunoglobulin E (IgE) in serum and the mRNA levels of interferon gamma 
      (IFN-gamma), interleukin 4 (IL-4) and IL-13 in the ear tissues, were also suppressed 
      by DHMEQ. DISCUSSION AND CONCLUSION: This study indicated that DHMEQ would be 
      useful for the treatment of AD.
FAU - Jiang, Xiaoxue
AU  - Jiang X
AD  - a Department of Pharmacology, School of Life Science and Biopharmaceutics , 
      Shenyang Pharmaceutical University , Shenyang , China.
FAU - Lan, Yi
AU  - Lan Y
AD  - a Department of Pharmacology, School of Life Science and Biopharmaceutics , 
      Shenyang Pharmaceutical University , Shenyang , China.
FAU - Wei, Bing
AU  - Wei B
AD  - a Department of Pharmacology, School of Life Science and Biopharmaceutics , 
      Shenyang Pharmaceutical University , Shenyang , China.
FAU - Dai, Cailing
AU  - Dai C
AD  - a Department of Pharmacology, School of Life Science and Biopharmaceutics , 
      Shenyang Pharmaceutical University , Shenyang , China.
FAU - Gu, Yaru
AU  - Gu Y
AD  - a Department of Pharmacology, School of Life Science and Biopharmaceutics , 
      Shenyang Pharmaceutical University , Shenyang , China.
FAU - Ma, Jun
AU  - Ma J
AD  - b Department of Research and Development , Shenzhen Wanhe Pharmaceutical Co., 
      Ltd. , Shenzhen , China.
FAU - Liu, Xiaoyan
AU  - Liu X
AD  - b Department of Research and Development , Shenzhen Wanhe Pharmaceutical Co., 
      Ltd. , Shenzhen , China.
FAU - Umezawa, Kazuo
AU  - Umezawa K
AD  - c Department of Molecular Target Medicine , Aichi Medical University School of 
      Medicine , Nagakute , Japan.
FAU - Zhang, Yuyang
AU  - Zhang Y
AD  - a Department of Pharmacology, School of Life Science and Biopharmaceutics , 
      Shenyang Pharmaceutical University , Shenyang , China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Immunopharmacol Immunotoxicol
JT  - Immunopharmacology and immunotoxicology
JID - 8800150
RN  - 0 (Benzamides)
RN  - 0 (Cyclohexanones)
RN  - 0 (Cytokines)
RN  - 0 (Dinitrochlorobenzene)
RN  - 0 (NF-kappa B)
RN  - 0 (Ointments)
RN  - 0 (dehydroxymethylepoxyquinomicin)
RN  - 15646-46-5 (Oxazolone)
SB  - IM
MH  - Animals
MH  - Benzamides/*pharmacology
MH  - Cyclohexanones/*pharmacology
MH  - Cytokines/immunology
MH  - *Dermatitis, Atopic/chemically induced/drug therapy/immunology/pathology
MH  - Dinitrochlorobenzene/*toxicity
MH  - *Epidermis/immunology/pathology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - NF-kappa B/*antagonists & inhibitors/immunology
MH  - Ointments
MH  - Oxazolone/*toxicity
OTO - NOTNLM
OT  - 2,4-dinitrochlorobenzene
OT  - BALB/c mice
OT  - Dehydroxymethylepoxyquinomicin
OT  - atopic dermatitis
OT  - immunoglobulin E
OT  - oxazolone
EDAT- 2017/04/19 06:00
MHDA- 2017/07/29 06:00
CRDT- 2017/04/19 06:00
PHST- 2017/04/19 06:00 [entrez]
PHST- 2017/04/19 06:00 [pubmed]
PHST- 2017/07/29 06:00 [medline]
AID - 10.1080/08923973.2017.1312436 [doi]
PST - ppublish
SO  - Immunopharmacol Immunotoxicol. 2017 Jun;39(3):157-164. doi: 
      10.1080/08923973.2017.1312436.